Abstract
CD4+ T cells that express the forkhead box P3 (FOXP3) transcription factor function as regulatory T (Treg) cells and hinder effective immune responses against cancer cells1,2,3. Abundant Treg cell infiltration into tumors is associated with poor clinical outcomes in various types of cancers3,4,5,6,7. However, the role of Treg cells is controversial in colorectal cancers (CRCs), in which FOXP3+ T cell infiltration indicated better prognosis in some studies6,7,8,9. Here we show that CRCs, which are commonly infiltrated by suppression-competent FOXP3hi Treg cells, can be classified into two types by the degree of additional infiltration of FOXP3lo nonsuppressive T cells10. The latter, which are distinguished from FOXP3+ Treg cells by non-expression of the naive T cell marker CD45RA and instability of FOXP3, secreted inflammatory cytokines. Indeed, CRCs with abundant infiltration of FOXP3lo T cells showed significantly better prognosis than those with predominantly FOXP3hi Treg cell infiltration. Development of such inflammatory FOXP3lo non-Treg cells may depend on secretion of interleukin (IL)-12 and transforming growth factor (TGF)-β by tissues and their presence was correlated with tumor invasion by intestinal bacteria, especially Fusobacterium nucleatum. Thus, functionally distinct subpopulations of tumor-infiltrating FOXP3+ T cells contribute in opposing ways to determining CRC prognosis. Depletion of FOXP3hi Treg cells from tumor tissues, which would augment antitumor immunity, could thus be used as an effective treatment strategy for CRCs and other cancers, whereas strategies that locally increase the population of FOXP3lo non-Treg cells could be used to suppress or prevent tumor formation.
Similar content being viewed by others
Accession codes
References
Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6, 345–352 (2005).
Zou, W. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307 (2006).
Nishikawa, H. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1–7 (2014).
Curiel, T.J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942–949 (2004).
Sato, E. et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102, 18538–18543 (2005).
deLeeuw, R.J., Kost, S.E., Kakal, J.A. & Nelson, B.H. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin. Cancer Res. 18, 3022–3029 (2012).
Sinicrope, F.A. et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137, 1270–1279 (2009).
Salama, P. et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186–192 (2009).
Frey, D.M. et al. High frequency of tumor-infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch-repair-proficient colorectal cancer patients. Int. J. Cancer 126, 2635–2643 (2010).
Miyara, M. et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30, 899–911 (2009).
Josefowicz, S.Z., Lu, L.F. & Rudensky, A.Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531–564 (2012).
Sakaguchi, S., Miyara, M., Costantino, C.M. & Hafler, D.A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490–500 (2010).
Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc. Natl. Acad. Sci. USA 110, 17945–17950 (2013).
Yamaguchi, T. et al. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression. Proc. Natl. Acad. Sci. USA 110, E2116–E2125 (2013).
Joller, N. et al. Treg cells expressing the co-inhibitory molecule TIGIT selectively inhibit pro-inflammatory TH1 and TH17 cell responses. Immunity 40, 569–581 (2014).
Blatner, N.R. et al. Expression of ROR-γt marks a pathogenic regulatory T cell subset in human colon cancer. Sci. Transl. Med. 4, 164ra159 (2012).
Ohkura, N. et al. T cell–receptor-stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37, 785–799 (2012).
Dejea, C.M. et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl. Acad. Sci. USA 111, 18321–18326 (2014).
Tosolini, M. et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 71, 1263–1271 (2011).
Galon, J. et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
Pagès, F. et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 27, 5944–5951 (2009).
Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
Rubinstein, M.R. et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin–β-catenin signaling via its FadA adhesin. Cell Host Microbe 14, 195–206 (2013).
Kostic, A.D. et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor–immune microenvironment. Cell Host Microbe 14, 207–215 (2013).
Atarashi, K. et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
Grivennikov, S.I. et al. Adenoma-linked barrier defects and microbial products drive IL-23- and IL-17–mediated tumor growth. Nature 491, 254–258 (2012).
Wu, P. et al. γδ T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785–800 (2014).
Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015).
Mima, K. et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol. 1, 653–661 (2015).
Mima, K. et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut http://dx.doi.org/10.1136/gutjnl-2015-310101 (2015).
Rech, A.J. et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl. Med. 4, 134ra62 (2012).
Vom Berg, J. et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection. J. Exp. Med. 210, 2803–2811 (2013).
Kim, S.W. et al. Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing. DNA Res. 20, 241–253 (2013).
Said, H.S. et al. Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers. DNA Res. 21, 15–25 (2014).
Acknowledgements
We appreciate sample collection by members of the Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University. We thank J.B. Wing for helpful discussions and critical reading of this manuscript, and Y. Tada, K. Teshima, Y. Funabiki and Y. Nakamura for technical assistance. This study was supported by Grants-in-Aid for Scientific Research (A grant no. 26253030 (S.S.), B grant no. 26290054 (H. Nishikawa) and Challenging Exploratory Research grant no. 26670581 (H. Nishikawa)) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Core Research for Evolutional Science and Technology (CREST) program from the Japan Science and Technology Agency (S.S.), an H24–Clinical Cancer Research–general-006 grant from the Health and Labor Sciences Research Grants program (H. Nishikawa) from the Japan Ministry of Health, Labor and Welfare Grants-in-aid program for Research on Applying Health Technology and a Cancer Research Institute CLIP grant (H. Nishikawa). This study was done in part as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan.
Author information
Authors and Affiliations
Contributions
H. Nishikawa and S.S. designed the research; T.S., H. Nishikawa, Y.N., D.S., K.A., Y.M., M. Hamaguchi, N.O., E.S., T.T. and W.S. performed experiments; T.S., H.W., H. Nagase, J.N., H.Y., S.T., M.M. and Y.D. collected samples and obtained clinical data; T.S., H. Nishikawa, H.W., W.S., H.M., M. Hattori, K.H., M.M., Y.D. and S.S. analyzed data; T.S., H. Nishikawa and S.S. wrote the paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Tables 1–2 and Supplementary Figures 1–13 (PDF 1504 kb)
Rights and permissions
About this article
Cite this article
Saito, T., Nishikawa, H., Wada, H. et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med 22, 679–684 (2016). https://doi.org/10.1038/nm.4086
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4086
- Springer Nature America, Inc.
This article is cited by
-
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
Nature Reviews Clinical Oncology (2024)
-
Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer
Scientific Reports (2024)
-
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer
British Journal of Cancer (2024)
-
Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition
Medical Oncology (2024)
-
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Molecular Diagnosis & Therapy (2024)